Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
US Department of Justice
Boehringer Ingelheim
McKinsey
McKesson
Accenture
Colorcon
Cantor Fitzgerald
Fuji
Chubb

Generated: January 21, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022254

« Back to Dashboard

NDA 022254 describes VIMPAT, which is a drug marketed by Ucb Inc and is included in three NDAs. It is available from three suppliers. There is one patent protecting this drug and three Paragraph IV challenges. Additional details are available on the VIMPAT profile page.

The generic ingredient in VIMPAT is lacosamide. There are twenty-one drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the lacosamide profile page.
Summary for 022254
Tradename:VIMPAT
Applicant:Ucb Inc
Ingredient:lacosamide
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 022254
Suppliers and Packaging for NDA: 022254
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VIMPAT lacosamide SOLUTION;INTRAVENOUS 022254 NDA UCB, Inc. 0131-1810 0131-1810-67 10 VIAL, GLASS in 1 CARTON (0131-1810-67) > 20 mL in 1 VIAL, GLASS

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:SOLUTION;INTRAVENOUSStrength200MG/20ML (10MG/ML)
Approval Date:Oct 28, 2008TE:RLD:Yes
Regulatory Exclusivity Expiration:Aug 29, 2017
Regulatory Exclusivity Use:INITIATION OF VIMPAT THERAPY WITH A LOADING DOSE OF 200MG
Regulatory Exclusivity Expiration:Aug 29, 2017
Regulatory Exclusivity Use:LOWER LIMIT OF 15 MINUTES FOR THE INFUSION DURATION
Regulatory Exclusivity Expiration:Aug 29, 2017
Regulatory Exclusivity Use:USE AS MONOTHERAPY IN THE TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS WITH EPILEPSY AGE 17 YEARS AND OLDER

Expired US Patents for NDA 022254

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ucb Inc VIMPAT lacosamide SOLUTION;INTRAVENOUS 022254-001 Oct 28, 2008 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Queensland Health
Fuji
Chinese Patent Office
Dow
Cerilliant
Accenture
Baxter
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot